Consensus Abivax

Equities

ABVX

FR0012333284

Market Closed - Euronext Paris Other stock markets 11:35:09 2024-05-10 am EDT			5-day change	1st Jan Change
13.38 ^EUR	-0.59%		-4.84%	+36.25%

May. 08	Abivax: four abstracts to be presented on obefazimod	CF
May. 08	Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024	CI

Evolution of the average Target Price on Abivax

Price target over the last 5 years

History of analyst recommendation changes

c7ee8a.pdIaZCBF7oJgxQrXMOZ-UYkw5-bz9CdvmYWY3k8qsdY.8-oiPUtom-sl90y5V683CfNv1aSUs30h_NbQtRcb27n_lko0cgfY2y-rOg~e00ef23f3ef2d92915a0d2fcc750f394

Analyst Recommendations on Abivax

Abivax: share price rises as two analysts express optimism	Apr. 29	CF
Piper Sandler Starts Abivax With Overweight Rating, $42 Price Target	Apr. 29	MT
Guggenheim Starts Abivax With Buy Rating, $50 Price Target	Apr. 29	MT
Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating	Apr. 11	MT
Abivax: in green, broker in support	23-08-22	CF
ABIVAX : Oddo BHF maintains its outperform rating	23-08-22	CF
Valneva: up sharply after positive analysis	23-06-16	CF
ABIVAX : Portzamparc downgrades its recommendation	23-06-09	CF
Abivax: no trend after unsurprising results	23-04-20	CF

More recommendations

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

5

Last Close Price

13.38 EUR

Average target price

37.59 EUR

Spread / Average Target

+180.94%

High Price Target

65 EUR

Spread / Highest target

+385.80%

Low Price Target

17.7 EUR

Spread / Lowest Target

+32.29%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Abivax

Guggenheim
Piper Sandler
Morgan Stanley

Ratings for Abivax

Trading Rating

Investor Rating

ESG Refinitiv

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW